ProfileGDS5678 / 1458802_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 82% 82% 83% 82% 88% 90% 85% 84% 78% 81% 79% 78% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7116281
GSM967853U87-EV human glioblastoma xenograft - Control 25.9243882
GSM967854U87-EV human glioblastoma xenograft - Control 35.8883882
GSM967855U87-EV human glioblastoma xenograft - Control 46.3021483
GSM967856U87-EV human glioblastoma xenograft - Control 55.9934482
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6206788
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9462990
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2733585
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1766584
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.422578
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7570781
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.547179
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3144578
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6078480